Belgium-headquartered biopharmaceutical company UCB is to sell its mature neurology and allergy business in China to Singapore-based asset management group CBC and investor Mubadala, based in Abu Dhabi, for $680 million.
US biopharma manufacturing and technology company National Resilience has entered into an agreement with Abu Dhabi investor Mubadala Investment Company to build a manufacturing plant in the United Arab Emirate’s biggest city. This will be the first GMP biopharma facility in the UAE.
Abu Dhabi National Oil Co (ADNOC) is taking over Mubadala’s holding in Borealis for an undisclosed sum. Once the transaction, which is subject to the usual conditions and regulatory approvals, is finalized, Borealis will be owned 25% by ADNOC and 75% by Austrian oil, gas and petrochemicals group OMV.
Abu-Dhabi sovereign wealth fund Mubadala Investment Co. has acquired a 1.9% stake in Sibur, Russia’s largest integrated petrochemicals producer. Terms were agreed prior to Sibur’s merger with compatriot petrochemical producer TAIF, which Mubadala said is “bound to further the company’s position in the polyolefins and rubbers markets, contribute to the pipeline of growth capex projects and unlock additional operational synergies.”
Italian multinational oil and gas group ENI has signed a Memorandum of Understanding with Mubadala Petroleum of Abu Dhabi to identify cooperation opportunities in the energy transition sector, including in the areas of hydrogen and carbon capture, utilization and storage.
